First patients diagnosed with rare disease with assist of AI algorithm are a fact

Sqilline and a leading pharmaceutical company have partnered to apply an AI algorithm and track high-risk patients for the rare disease of Transthyretin amyloid polyneuropathy (TTR).

The aim was to support neurologists find previously undiagnosed patients by assisting them with digital technology.

For this project, Danny Platform evaluated the electronic health records of 10 leading neurological hospitals. The proprietary algorithm, with carefully pre-defined including/excluding criteria, searched for possible undiagnosed patients.


  • Digital data collection based on electronic health records
  • 10 Leading hospitals
  • Filed – neurology
  • Specified incl/excl criteria based on symptoms are applied to identify undiagnosed patients


  • TTR is a progressive and ultimately, a fatal rare disease that destroys nerve cells governing various bodily functions
  • Symptoms are often similar to other diseases and difficult to recognize
  • Limited awareness
  • When structured Electronic health records hold important information
  • Most symptoms are described in free text in the epicrisis


  • 3 443 Total electronic epicrisis processed in seconds from all hospitals
  • 556 Total number of patient records selected by the algorithm based on the symptoms criteria
  • 30 Patient records marked as eligible

Several patients are diagnosed with TTR by genetic test after the algorithm selection


  • Systematic screening of EHRs with specified criteria can identify in seconds high-risk cases for rare diseases even after patient hospitalization
  • Increased awareness and understanding of rare diseases
  • Empowering physicians with digital technology is key to patients-centricity and precision medicine
  • Improving potential collaboration between the leading hospitals (neurology, oncology) accelerates patient diagnostics


Danny Platform via ML algorithms selected all patients being hospitalized for neurological diseases (G60, G61, G62, G63, G64) with the specific key symptoms and symptom weight value.

The system then creates a cohort of high-risk patients for Transthyretin amyloid polyneuropathy (TTR) to be further reviewed and examined by neurologists.

Reaching the final diagnosis was a process based on a thorough clinical evaluation, detailed screening of patient profiles, application ML algorithms, and finally confirmation by a genetic test.

Sqilline’s ambition and focus are to support physicians accelerate earlier diagnosis and treatment for patients with rare diseases so they can lead better, more fulfilling lives.

Share this article:

More News & Highlights


What if we could change the common approach to clinical trials?

Desislava Mihaylova, CEO and Founder, Sqilline At Sqilline, we listen to the people we work with and often ask ourselves what if… This was the...



Breaking Barriers in Healthcare Data Interoperability: The Danny Platform Solutions

Mihail Jekov, CTO and Partner, Sqilline Electronic Health Records (EHRs) contain a large quantity of machine-readable data. However, institutions choose different EHR vendors, and the...



Sqilline and Fundeni Clinical Institute unite through a strategic partnership for access to high-quality Real-World Data

Sqilline is proud to announce its partnership with The Fundeni Clinical Institute in Romania. The focus of this partnership is the deployment of the analytic...